- Stocks
- Pharma & Healthcare
- Astec LifeSciences
Astec LifeSciences share price
NSE: ASTECPharma & HealthcareAgricultural Inputs
Astec LifeSciences at a glance
Astec LifeSciences (NSE: ASTEC) closed at ₹700.20 on 22 Oct 2026, up 6.41% on the day. With a market capitalisation of ₹1,560 Cr, it ranks 1251st by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Agricultural Inputs.
Its return on equity was −20.7% in FY26. Over the past year the share price has fallen 5.5%. Its 52-week range is ₹513.40 (23 Mar 2026) to ₹941.75 (26 Nov 2025); the last close is 25.6% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹84 Cr (−8.3% year on year) and net profit −₹19 Cr, on a consolidated basis. Promoters held 71.96% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹1,560 CrRank 1251 on NSE
- Price to book
- 3.08×FY26
- EPS (TTM)
- −₹30.27to Q1 FY27
- ROE
- −20.7%FY26
- ROCE
- −10.0%FY26
- Debt to equity
- 1.15FY26
- Net profit margin
- −18.0%FY26
- Book value / share
- ₹175.30FY26
- 52-week high
- ₹941.7526 Nov 2025
- 52-week low
- ₹513.4023 Mar 2026
- 1-year return
- −5.5%
- RSI (14-day)
- 50
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +6.41% | −3.4% | −1.8% | +3.8% | −5.5% |
Astec LifeSciences quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹99 Cr | ₹94 Cr | ₹120 Cr | ₹91 Cr | ₹74 Cr | ₹125 Cr | ₹159 Cr | ₹84 Cr |
| Revenue YoY | −11.0% | +84.8% | −22.3% | +31.3% | −25.2% | +32.9% | +32.7% | −8.3% |
| Net profit | −₹39 Cr | −₹40 Cr | −₹16 Cr | −₹33 Cr | −₹24 Cr | −₹16 Cr | −₹8 Cr | −₹19 Cr |
| Net profit YoY | — | — | — | — | — | — | — | — |
| Net margin | −39.1% | −43.0% | −13.5% | −36.3% | −33.1% | −12.6% | −4.9% | −22.4% |
| EPS | −₹19.66 | −₹20.59 | −₹8.20 | −₹16.85 | −₹11.35 | −₹7.04 | −₹3.48 | −₹8.40 |
Astec LifeSciences financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹555 Cr | ₹677 Cr | ₹628 Cr | ₹458 Cr | ₹381 Cr | ₹448 Cr |
| Operating profit | ₹89 Cr | ₹121 Cr | ₹35 Cr | −₹62 Cr | −₹141 Cr | −₹79 Cr |
| Net profit | ₹65 Cr | ₹90 Cr | ₹26 Cr | −₹47 Cr | −₹135 Cr | −₹81 Cr |
| EPS (₹) | ₹33.00 | ₹46.00 | ₹13.00 | −₹24.00 | −₹69.00 | −₹38.00 |
| Cash from operations | −₹8 Cr | ₹24 Cr | ₹75 Cr | ₹10 Cr | −₹8 Cr | −₹81 Cr |
| Total debt | ₹40 Cr | ₹0 Cr | ₹11 Cr | ₹199 Cr | ₹280 Cr | ₹50 Cr |
| Shareholders' equity | ₹309 Cr | ₹397 Cr | ₹419 Cr | ₹369 Cr | ₹235 Cr | ₹391 Cr |
Astec LifeSciences shareholding pattern
| Holder | 30 Jun 2025 | 29 Jul 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 70.87% | 72.42% | 72.42% | 71.97% | 71.97% | 71.96% |
| Foreign institutions | 0.02% | 0.02% | 0.00% | 0.04% | 0.02% | 0.01% |
| Domestic institutions | 4.26% | 4.01% | 4.01% | 3.17% | 3.34% | 3.33% |
| Non-institutions | 24.84% | 23.55% | 23.57% | 24.82% | 24.67% | 24.69% |
Astec LifeSciences vs peers
The listed Pharma & Healthcare companies nearest to Astec LifeSciences by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| KRSNAAKrsnaa Diagnostics | ₹510.75 | −0.79% | −38.5% | ₹1,657 Cr | 16.5 | — |
| JLHLJupiter Life Line Hospitals | ₹244.75 | −0.87% | −20.0% | ₹1,605 Cr | 8.3 | — |
| ASTECAstec LifeSciences | ₹700.20 | +6.41% | −5.5% | ₹1,560 Cr | — | — |
| SURAKSHASuraksha Diagnostic | ₹294.05 | +1.75% | +1.1% | ₹1,531 Cr | 47.6 | — |
| GKSLGujarat Kidney And Super Speciality | ₹183.00 | +0.53% | — | ₹1,443 Cr | 73.5 | — |
| AMRUTANJANAmrutanjan Health Care | ₹496.20 | +0.45% | −29.1% | ₹1,435 Cr | 24.8 | — |
| JAGSNPHARMJagsonpal Ser | ₹216.03 | −1.13% | +2.0% | ₹1,422 Cr | 34.2 | — |
Ask anything about Astec LifeSciences
Pivot answers on the live chart with evidence you can check, and tests strategies against ASTEC's own history. Try: “Why has ASTEC moved over the last three months?” · “Backtest a 50-day moving-average crossover on ASTEC over five years” · “Compare ASTEC with KRSNAA on margins and valuation”
Frequently asked questions about Astec LifeSciences
What is the share price of Astec LifeSciences today?
Astec LifeSciences (NSE: ASTEC) last closed at ₹700.20 on 22 Oct 2026. Its 52-week high is ₹941.75 and its 52-week low is ₹513.40.
What is the market cap of Astec LifeSciences?
Astec LifeSciences' market capitalisation is ₹1,560 Cr (₹1,560 Cr) at the 22 Oct 2026 close, ranking 1251st among the NSE companies Pivot tracks.
What is the ROE and ROCE of Astec LifeSciences?
Return on equity was −20.7% in FY26 and return on capital employed was −10.0% in FY26 (consolidated figures).
Is Astec LifeSciences a debt-free company?
No. Astec LifeSciences' debt-to-equity ratio was 1.15 in FY26, with total debt of ₹50 Cr.
What were Astec LifeSciences' latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Astec LifeSciences reported revenue of ₹84 Cr, −8.3% year on year, and net profit of −₹19 Cr.
How has Astec LifeSciences stock performed over the last year?
Astec LifeSciences' share price has fallen 5.5% over the past year, +3.8% over three months and −1.8% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Astec LifeSciences?
As of 30 Jun 2026: promoters 71.96%, foreign institutions 0.01%, domestic institutions 3.33%, non-institutions 24.69%.
Who are Astec LifeSciences' competitors?
The listed Pharma & Healthcare companies closest to Astec LifeSciences by market cap are Krsnaa Diagnostics, Jupiter Life Line Hospitals, Suraksha Diagnostic, Gujarat Kidney And Super Speciality, Amrutanjan Health Care and Jagsonpal Ser.
Is Astec LifeSciences a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Astec LifeSciences' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ASTEC against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with A · all NSE stocks · this page as text